Dosage protocol · Immune & Inflammation
LL-37 5 mg
Typical daily range: 100–400 µg once daily (gradual titration).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical daily range: 100–400 µg once daily (gradual titration).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 µg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks; avoid freeze–thaw cycles.
Reconstitution
LL-37 dosage chart
| Week | Dose | Draw |
|---|---|---|
| Week 1 | 50 µg | 3 units0.03 mL |
| Week 2 | 100 µg | 6 units0.06 mL |
| Week 3 | 150 µg | 9 units0.09 mL |
| Week 4 | 200 µg | 12 units0.12 mL |
| Week 5 | 250 µg | 15 units0.15 mL |
| Week 6 | 300 µg | 18 units0.18 mL |
| Week 7 | 350 µg | 21 units0.21 mL |
| Week 8 | 400 µg | 24 units0.24 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
LL-37 is not a synthetic laboratory invention. It is a naturally occurring human peptide, produced by cleaving a larger precursor protein called hCAP-18, which is encoded by the CAMP gene.[1] Neutrophils, skin cells, and other epithelial tissue produce it as part of the body's innate immune system, making LL-37 fundamentally different from engineered growth-hormone-style research peptides.
Its name reflects its structure: it begins with two leucines and contains 37 amino acids total.[2] LL-37 folds into an amphipathic alpha-helix, with one face attracted to fats and the other to water, a shape that helps it interact with microbial cell membranes and immune cells.
Benefits & side effects
LL-37's role in normal human biology is well established: it is a documented, naturally produced component of innate immunity at skin, airway, and gut surfaces.[3] Laboratory studies show activity against a range of bacteria, fungi, and some viruses under controlled conditions, though lab activity does not automatically predict effectiveness in a real infection.[5]
Human clinical evidence is limited but not absent. A randomized, placebo-controlled trial tested topical LL-37 at 0.5 mg/mL and 1.6 mg/mL in patients with hard-to-heal venous leg ulcers and reported improved wound healing with acceptable tolerability.[7] That is a genuine, if narrow, positive human signal — but it is a single trial in one wound type using one topical formulation, not evidence supporting broader antimicrobial, immune, or dermatologic use.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.